New hope for broad spectrum cancer drug
Laboratory tests by scientists at The Institute of Cancer Research in London have revealed that a kinase inhibitor known as AT13148 could have potential as a broad spectrum cancer drug.
UK Discovered Prostate Cancer Drug Launches In Britain
A new life-extending drug to treat patients with advanced prostate cancer, developed by The Institute of Cancer Research (ICR) and The Royal Marsden Hospital, has now received its UK license. There are calls for the drug, abiraterone acetate, which is marketed by Janssen under the trade name Zytiga, to receive a speedy decision from the